Thursday, May 29, 2014

Christie’s Magificent Jewels in New York April 16

A pair of D color, internally flawless type IIa diamond drop earrings weighing 22.60 and 22.31 carats and set in platinum, sold for $8,565,000.
Christie’s kicked off their spring auction season in New York with a +$60 million sale.

A 6.10-carat type IIa pink diamond set in a platinum and 18k rose gold ring with baguette diamonds by Harry Winston, sold for $5,765,000

A 40.43-carat, D color, type IIa oval diamond and platinum ring, sold for $7,669,000

A necklace featuring a 24.53-carat, D color, type IIa, pear-shaped diamond pendant on a platinum chain, sold for $2,225,000.

A 2.49-carat yellowish green diamond in a diamond-set platinum ring by JAR, sold for $1,805,000.

A 15.75-carat vivid yellow diamond in a diamond pavé-set platinum ring by JAR, sold for $809,000.

An emerald and diamond brooch by Van Cleef & Arpels, featuring a 7.77-carat central emerald, sold for $425,000

A 50.05-carat briolette D color, flawless diamond with a $5.5 – $7.5 million estimate failed to sell.

A 20.10-carat D color diamond set in a platinum ring with tapered baguette diamonds, sold for $2,461,000.
A large ruby and diamond necklace by James W. Currens for Fai Dee known as the ‘Red Emperor’.

Composed of 104.51 carats of exceptional heart and pear-shaped rubies with 59.05 carats of diamonds. This necklace sold for $9.9 million at Sotheby’s Magnificent Jewels Hong Kong April 7 Auction.

See ----->
See ----->
See ----->
See ----->

Generic 468 x 60banner

Trimel Pharmaceuticals Corporation - TRL.t

Trimel Pharmaceuticals Corporation - TRL.t is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.

The Corporation holds a licence for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system (“TriVair™”).

On May 28, 2014 the company reported NEWS

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto™ (testosterone), formerly CompleoTRT™, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children.

“In my practice I regularly encounter men demonstrating symptoms of hypogonadism and physicians will increasingly see this as the North American population ages,” said Dr. Jeffrey Rosen, the medical director and founder of Clinical Research of South Florida (CRSA). “For these patients seeking to restore their testosterone levels, Natesto™ will offer an alternative delivery system that is safer and more convenient than the other options currently available on the market.”

Monday, May 26, 2014

Welcome Rakuten Global Market

Looking for Japanese Products - Find thousands of merchants with millions of unique products-Rakuten Ichiba There are more than 7 Million members in Japan's No.1 Internet shopping mall “Rakuten-Ichiba”.

You can choose from over 400,000 items. Each product is delivered directly from each shop all the way to your doorstep, wherever you are. This service has been enjoyed by people in more than 50 countries.

Enjoy Japanese shopping!
Looking for Japanese Products - Find thousands of merchants with millions of unique products-Rakuten Ichiba

Saturday, May 24, 2014

The destruction of the Chrysler Turbine Cars

Called “one of the greatest publicity stunts in automotive history,” the Chrysler Turbine car program ranks as one of the most unique automotive experiments ever, and its story continues to captivate 50 years later.

By the spring of 1963, Chrysler’s experiments with turbine-powered cars were well known. Chrysler was the only automaker to take the next step and start to develop a turbine-powered car available to the public. In May of 1963, Chrysler not only introduced the Turbine car, it also announced that it would make 50 of the cars available for three-month-long test drives.
Turbine cars featured two-door four-passenger sedan bodies built by Ghia that shared nothing with any other Chrysler Corporation product.
Under the hood, they featured Chrysler’s fourth-generation A-381 regenerator turbine engine, good for 425-pound-feet of torque, hooked up to modified TorqueFlite three-speed automatic transmissions.

Aside from the five prototypes built by Ghia, all 50 came in the same configuration: bronze paint, black vinyl top, and bronze leather interior.
Acceleration proved to be no problem to the turbine driven cars (0 - 100 km/h in approx 10 seconds), but problems were experienced by drivers. These included fuel consumption (at best around 12 mpg) and cabin heat that was being generated by the turbine motor. When Chrysler decided that it was never going to become a commercial proposition, they destroyed 40 of the prototypes, with the remaining 10 being given to museums.
"The decision to destroy the Turbine cars was pragmatic. Anything done outside of the control of the corporation could potentially create all sorts of PR headaches and diminish the good image effects from the program in the eyes of the public. Nobody wanted a bunch of those bodies running around with piston engines in them, etc., and they sure would not let them out of hand with the gas turbines still installed. Best and most logical decision – destroy them."
Jay Leno owns a Chrysler Turbine Car--one of only two running examples in private hands. Because he bought it directly from Chrysler, he is the first owner of the machine seen here: Number 34, according to a polished piece of trim located on the inner windshield.

Leno calls the Turbine Car "the most collectible post-war car ever."

3,500-year-old tribal gold lunula found

Treasure hunter David Spohr was searching in Tarrant Valley, Dorset when he found a 3,500-year-old tribal gold necklace called a Lunula. - meaning 'little moon' in Latin due to their shape.

The necklaces were worn by ancient tribal leaders as a symbol of power.
The lunula unearthed by Mr Spohr weighs 71.5 grams, and is one of only a handful ever found in mainland Britain - and the first to be discovered using a metal detector. Only three others have ever been found in Britain, the last of which was dug up in Wales in 1869.

The necklace could be worth as much as £20,000. The find would have been worth even more but it is thought to have been damaged by a farmer's plough.

Thursday, May 22, 2014

Toronto Dominion Bank - TD.t

Toronto Dominion Bank - TD.t is headquartered in Toronto, Canada, with offices around the world. TD Bank Group offers a full range of financial products and services.

Toronto-Dominion Bank surpassed Royal Bank of Canada as the country’s largest lender by assets after expansion into U.S. consumer lending. TD reported $862.5 billion in total assets as of Oct. 31, 2013.

On May 22, 2014 the company reported NUMBERS

TD Bank Group ("TD" or the "Bank") today announced its financial results for the second quarter ended April 30, 2014. Results for the quarter reflected good earnings contributions from all business segments.

"By any measure, our results this quarter were outstanding," said Ed Clark, Group President and Chief Executive Officer. "Adjusted earnings were $2.1 billion, up 14% from the same period last year, driven by strong organic growth and contributions from our recent acquisitions. These results demonstrate the considerable earnings power of our business model."

SECOND QUARTER FINANCIAL HIGHLIGHTS, compared with the second quarter a year ago:

• Reported diluted earnings per share were $1.04, compared with $0.89.
• Adjusted diluted earnings per share were $1.09, compared with $0.95.
• Reported net income was $1,988 million, compared with $1,717 million.
• Adjusted net income was $2,074 million, compared with $1,827 million.

YEAR-TO-DATE FINANCIAL HIGHLIGHTS, six months ended April 30, 2014, compared with the corresponding period a year ago:

• Reported diluted earnings per share were $2.11, compared with $1.82.
• Adjusted diluted earnings per share were $2.15, compared with $1.94.
• Reported net income was $4,030 million, compared with $3,501 million.
• Adjusted net income was $4,098 million, compared with $3,737 million.